“Ukatamanga weka utamangisa, tikatamanga awili, tifikapatali" - When you run alone, you run fast. When you run together, you run fast - Zambian Proverb


Research and Training Programme


Reply to Reisler et al. Lanini S, Portella G, Vairo F, Di Caro A, Kobinger G, Zumla A, Ippolito G. Clin Infect Dis. 2017 Dec 20.

Outcomes of multidrug-resistant tuberculosis in Zambia: a cohort analysis. Kapata N, Grobusch MP, Chongwe G, Chanda-Kapata P, Ngosa W, Tembo M, Musonda S, Katemangwe P, Bates M, Mwaba P, Zumla A, Cobelens F. Infection. 2017 Dec;45(6):831-839.

Ending the Global Tuberculosis Epidemic by 2030 - The Moscow Declaration and achieving a Major Translational Change in Delivery of TB Healthcare. Petersen E, Blumberg L, Wilson ME, Zumla A. Int J Infect Dis. 2017 Dec;65:156-158.

Advancing political will to end the tuberculosis epidemic. Herbert N, Masham BS, Suttie BA, Sharma V, Albani S, Domenti O, Flurry R, Oliver M, Zumla A. Lancet Infect Dis. 2017 Nov 15.

A large ongoing outbreak of hepatitis A predominantly affecting young males in Lazio, Italy; August 2016 - March 2017. Lanini S, Minosse C, Vairo F, Garbuglia A, Di Bari V, Agresta A, Rezza G, Puro V, Pendenza A, Loffredo MR, Scognamiglio P, Zumla A, Panella V, Ippolito G, Capobianchi MR; Gruppo Laziale Sorveglianza Epatiti Virali (GLaSEV). PLoS One. 2017 Nov 10;12(11)

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis. Murphy ME, Phillips PPJ, Mendel CM, Bongard E, Bateson ALC, Hunt R, Murthy S, Singh KP, Brown M, Crook AM, Nunn AJ, Meredith SK, Lipman M, McHugh TD, Gillespie SH; REMoxTB Consortium.

BMC Med. 2017 Oct 27;15(1):192.

Aiming for zero tuberculosis transmission in low-burden countries. Marais BJ, Walker TM, Cirillo DM, Raviglione M, Abubakar I, van der Werf MJ, Boehme C, Niemann S, Castro KG, Zumla A, Sintchenko V, Crook DW. Lancet Respir Med. 2017 Nov;5(11):846-848.

Tuberculosis among older adults in Zambia: burden and characteristics among a neglected group. Coffman J, Chanda-Kapata P, Marais BJ, Kapata N, Zumla A, Negin J. BMC Public Health. 2017 Oct 12;17(1):804. doi: 10.1186/s12889-017-4836-0.

Relationship between viremia and specific organ damage in Ebola patients: a cohort study. Lanini S, Portella G, Vairo F, Kobinger GP, Pesenti A, Langer M, Kabia S, Brogiato G, Amone J, Castilletti C, Miccio R, Capobianchi MR, Strada G, Zumla A, Di Caro A, Ippolito G; INMI-EMERGENCY EBOV Sierra Leone Study group. Clin Infect Dis. 2017 Aug 20.

Undiagnosed Active Pulmonary Tuberculosis among Pilgrims during the 2015 Hajj Mass Gathering: A Prospective Cross-sectional Study. Yezli S, Zumla A, Yassin Y, Al-Shangiti AM, Mohamed G, Turkistani AM, Alotaibi B. Am J Trop Med Hyg. 2017 Sep 5.

The challenges of cholera at the 2017 Hajj pilgrimage. Zumla A, McCloskey B, Endericks T, Azhar EI, Petersen E. Lancet Infect Dis. 2017 Sep;17(9):895-897. doi: 10.1016/S1473-3099(17)30454-1. Epub 2017 Aug 10

Outcomes of multidrug-resistant tuberculosis in Zambia: a cohort analysis. Kapata N, Grobusch MP, Chongwe G, Chanda-Kapata P, Ngosa W, Tembo M, Musonda S, Katemangwe P, Bates M, Mwaba P, Zumla A, Cobelens F. Infection. 2017 Aug 4. doi: 10.1007/s15010-017-1054-8.

Human Zika infection induces a reduction of IFN-γ producing CD4 T-cells and a parallel expansion of effector Vδ2 T-cells. Cimini E, Castilletti C, Sacchi A, Casetti R, Bordoni V, Romanelli A, Turchi F, Martini F, Tumino N, Nicastri E, Corpolongo A, Di Caro A, Kobinger G, Zumla A, Capobianchi MR, Ippolito G, Agrati C.

Sci Rep. 2017 Jul 24;7(1):6313.

Non-Steroidal Anti-inflammatory Drugs As Host-Directed Therapy for Tuberculosis: A Systematic Review. Kroesen VM, Gröschel MI, Martinson N, Zumla A, Maeurer M, van der Werf TS, Vilaplana C. Front Immunol. 2017 Jun 30;8:772.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5).

Enhancing preparedness for tackling new epidemic threats.  Zumla A, Ippolito G, McCloskey B, Bates M, Ansumana R, Heymann D, Kock R, Ntoumi F. May 18, 2017 http://dx.doi.org/10.1016/ S2213-2600(17)30189-3 PDF

Clinical trial research in focus: overcoming barriers in MDR-TB clinical trials. Zumla A, Abubakar I. Lancet Respir Med. 2017 Apr;5(4):247-248.

Health systems in the Republic of Congo: challenges and opportunities for implementing tuberculosis and HIV collaborative service, research, and training activities. Linguissi LS, Gwom LC, Nkenfou CN, Bates M, Petersen E, Zumla A, Ntoumi F. Int J Infect Dis. 2017 Mar;56:62-67.

Performance of the Xpert MTB/RIF assay in the diagnosis of tuberculosis in formalin-fixed, paraffin-embedded tissues. Polepole P, Kabwe M, Kasonde M, Tembo J, Shibemba A, O'Grady J, Kapata N, Zumla A, Bates M. Int J Mycobacteriol. 2017 Jan-Mar;6(1):87-93.

Effectiveness of interventions for diagnosis and treatment of tuberculosis in hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review. Heuvelings CC, de Vries SG, Greve PF, Visser BJ, Bélard S, Janssen S, Cremers AL, Spijker R, Shaw B, Hill RA, Zumla A, Sandgren A, van der Werf MJ, Grobusch MP. Lancet Infect Dis. 2017 Mar 10.

Barriers and facilitators to the uptake of tuberculosis diagnostic and treatment services by hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review of qualitative literature. de Vries SG, Cremers AL, Heuvelings CC, Greve PF, Visser BJ, Bélard S, Janssen S, Spijker R, Shaw B, Hill RA, Zumla A, van der Werf MJ, Sandgren A, Grobusch MP. Lancet Infect Dis. 2017 Mar 10.

IL-7δ5 protein is expressed in human tissues and induces expression of the oxidized low density lipoprotein receptor 1 (OLR1) in CD14+ monocytes. Rane L, Rahman S, Magalhaes I, Ambati A, Andersson J, Zumla A, Brighenti S, Maeurer MJ. Int J Infect Dis. 2017 Mar 6.

Agents of change: The role of healthcare workers in the prevention of nosocomial and occupational tuberculosis. Nathavitharana RR, Bond P, Dramowski A, Kotze K, Lederer P, Oxley I, Peters JA, Rossouw C, van der Westhuizen HM, Willems B, Ting TX, von Delft A, von Delft D, Duarte R, Nardell E, Zumla A. Presse Med. 2017 Feb 27.

The cursed duet today: Tuberculosis and HIV-coinfection.Tiberi S, Carvalho AC, Sulis G, Vaghela D, Rendon A, Mello FC, Rahman A, Matin N, Zumla A, Pontali E. Presse Med. 2017 Feb 27.

World TB Day 2017: Advances, Challenges and Opportunities in the "End-TB" Era. Petersen E, Maeurer M, Marais B, Migliori GB, Mwaba P, Ntoumi F, Vilaplana C, Kim K, Schito M, Zumla A. Int J Infect Dis. 2017 Mar;56:1-5.

Strong anti-Epstein Barr virus (EBV) or cytomegalovirus (CMV) cellular immune responses predict survival and a favourable response to anti-tuberculosis therapy. Nagu T, Aboud S, Rao M, Matee M, Axelsson R, Valentini D, Mugusi F, Zumla A, Maeurer M. Int J Infect Dis. 2017 Mar;56:136-139.

Immune recognition surface construction of Mycobacterium tuberculosis epitope-specific antibody responses in tuberculosis patients identified by peptide microarrays. Valentini D, Rao M, Ferrara G, Perkins M, Dodoo E, Zumla A, Maeurer M. Int J Infect Dis. 2017 Mar;56:155-166.

De-isolation of patients with pulmonary tuberculosis after start of treatment - clear, unequivocal guidelines are missing. Petersen E, Khamis F, Migliori GB, Bay JG, Marais B, Wejse C, Zumla A. Int J Infect Dis. 2017 Feb 2.

Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Rao M, Valentini D, Dodoo E, Zumla A, Maeurer M. Int J Infect Dis. 2017 Feb 2.

Mycobacterium tuberculosis proteins involved in cell wall lipid biosynthesis improve BCG vaccine efficacy in a murine TB model. Rao M, Cadieux N, Fitzpatrick M, Reed S, Arsenian S, Valentini D, Parida S, Dodoo E, Zumla A, Maeurer M. Int J Infect Dis. 2017 Feb 1.

Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy. Nagu TJ, Aboud S, Mwiru R, Matee MI, Rao M, Fawzi WW, Zumla A, Maeurer MJ, Mugusi F. Int J Infect Dis. 2017 Feb 1.

Peptide microarray-based characterisation of antibody responses to host proteins after Bacille Calmette-Guérin vaccination. Valentini D, Rao M, Rane L, Rahman S, Axelsson-Robertson R, Heuchel R, Löhr M, Hoft D, Brighenti S, Zumla A, Maeurer M. Int J Infect Dis. 2017 Feb 1.

Humoral immune profiling of mycobacterial antigen recognition in sarcoidosis and Löfgren's syndrome using high-content peptide microarrays. Ferrara G, Valentini D, Rao M, Wahlström J, Grunewald J, Larsson LO, Brighenti S, Dodoo E, Zumla A, Maeurer M. Int J Infect Dis. 2017 Jan 31

The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. Girardi E, Schepisi MS, Goletti D, Bates M, Mwaba P, Yeboah-Manu D, Ntoumi F, Palmieri F, Maeurer M, Zumla A, Ippolito G. Int J Infect Dis. 2017 Jan 30.

Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient. Biava M, Caglioti C, Bordi L, Castilletti C, Colavita F, Quartu S, Nicastri E, Lauria FN, Petrosillo N, Lanini S, Hoenen T, Kobinger G, Zumla A, Di Caro A, Ippolito G, Capobianchi MR, Lalle E. PLoS Pathog. 2017 Jan 5;13(1)